CN115887602B - Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device - Google Patents
Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device Download PDFInfo
- Publication number
- CN115887602B CN115887602B CN202211556055.1A CN202211556055A CN115887602B CN 115887602 B CN115887602 B CN 115887602B CN 202211556055 A CN202211556055 A CN 202211556055A CN 115887602 B CN115887602 B CN 115887602B
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- pharmaceutical composition
- resisting
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 176
- 208000009608 Papillomavirus Infections Diseases 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 10
- 235000011837 pasties Nutrition 0.000 claims description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 9
- 241001313857 Bletilla striata Species 0.000 claims description 9
- 241001071917 Lithospermum Species 0.000 claims description 9
- 240000001659 Oldenlandia diffusa Species 0.000 claims description 9
- 240000007643 Phytolacca americana Species 0.000 claims description 9
- 235000009074 Phytolacca americana Nutrition 0.000 claims description 9
- 229940116229 borneol Drugs 0.000 claims description 9
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 9
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 9
- 240000009138 Curcuma zedoaria Species 0.000 claims description 8
- 235000006533 astragalus Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 7
- 210000004233 talus Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 24
- 239000000203 mixture Substances 0.000 abstract description 23
- 239000007921 spray Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 18
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 12
- 210000001215 vagina Anatomy 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 206010008263 Cervical dysplasia Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000011068 loading method Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 101710153650 Heparin cofactor 2 Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for resisting papilloma virus infection, a preparation method and a medicine feeding device, which solve the technical problems that the traditional Chinese medicine composition for resisting papilloma virus infection is relatively complex in formula and inconvenient to use. The traditional Chinese medicine raw materials of the pharmaceutical composition comprise the following components: the medicine feeding device is used for feeding medicine compositions, comprises a medicine feeding tube and a medicine feeder, and has the advantages of simple formula, good effect, convenience in medicine feeding and the like.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition for resisting papillomavirus infection, a preparation method and a medicine feeding device.
Background
Persistent infection with high risk papillomavirus (HR-HPV) in the female genital tract is closely related to the progression of cervical high-grade squamous intraepithelial lesions (high-grade squamous intraepithelial lesion, HSIL) to invasive cervical cancer, and thus, it is necessary to reduce the rate of persistent infection with HPV viruses and to block the progression of cervical intraepithelial neoplasia (cervical intraepithelial neoplasia, CIN) disease, which is a difficult and important point of clinical treatment, follow-up.
At present, western medicine clinic mainly carries out periodic follow-up visit on interferon or no medicine aiming at cervical HR-HPV infection, LEEP operation or hysterectomy treatment is mostly adopted for patients with HSIL, western medicine which has evidence-based medical evidence and can resist persistent HPV infection is few through clinical research test, and medicine therapy has the problems of long treatment period, low virus negative conversion rate, medicine resistance, high recurrence rate, high cost and the like in the application process, and is always controversial.
In order to overcome the defects of western medicines in treatment, a practical Chinese medicinal preparation with smaller research side effects and low price is of great significance for resisting papillomavirus infection, and in the existing Chinese medicinal research technology, a plurality of Chinese medicinal compositions for resisting papillomavirus infection are developed, but the formula is relatively complex and the use is inconvenient.
Therefore, it is necessary to develop a new formulation of the traditional Chinese medicine composition and solve the problem of inconvenient use against the deficiency of the traditional Chinese medicine composition for resisting papillomavirus infection.
Disclosure of Invention
The technical problems to be solved by the invention are as follows: the traditional Chinese medicine composition for resisting papillomavirus infection has relatively complex formula and is inconvenient to use.
The invention is realized by the following technical scheme:
the medicine composition for resisting papillomavirus infection comprises the following raw materials: radix astragali, herba Hedyotidis Diffusae, rhizoma Bletillae, curcumae rhizoma, radix Phytolaccae, radix Arnebiae and Borneolum Syntheticum.
The invention has the advantages of simple prescription and treatment principle by organically combining 7 medicines, and the invention has the following steps: strengthening body resistance, removing toxic substances, removing blood stasis and promoting granulation.
The astragalus root in the prescription has the effects of tonifying qi and yang, expelling toxin and promoting pus, healing sore and promoting tissue regeneration, the oldenlandia diffusa and the two medicines of tonifying qi and clearing toxin are all monarch medicines, the bletilla striata and the lithospermum have the effects of cooling blood and activating blood, removing necrotic tissue and promoting tissue regeneration, and the pokeberry root and the curcuma zedoary have the effects of activating blood, dissolving stasis and promoting diuresis, and detumescence and resolving hard mass, are auxiliary medicines, and the borneol has the effects of removing necrotic tissue and promoting tissue regeneration, detumescence and relieving pain, and the whole prescription has the effects of tonifying qi and clearing toxin and activating blood and promoting tissue regeneration.
Astragalus mongholicus has the effects of enhancing organism immunity, improving phagocytic capacity of phagocytes, increasing leukocyte count of peripheral blood vessels and the like, and rhizoma curcumae contains more effective anticancer and antiviral components such as Ji Matong, curcumenol, curcuminoid, curcumin and the like, and the components have the effects of resisting inflammation, relieving pain, removing necrotic tissue and promoting granulation, can resist episomal viruses, and also has the inhibiting effect on viral gene fragments integrated on host cell chromosomes. The borneol has good anti-inflammatory and analgesic effects, and the pokeberry root, the bletilla striata, the lithospermum, the oldenlandia diffusa and the like have the effects of anti-inflammatory, antivirus, anti-tumor, immunity regulation and the like.
The preferred pharmaceutical composition for resisting papilloma virus infection comprises the following raw materials in parts by weight:
3-5 parts of raw astragalus, 3-5 parts of oldenlandia diffusa, 1-3 parts of bletilla striata, 1-3 parts of curcuma zedoary, 1-3 parts of pokeberry root, 1-3 parts of lithospermum and 0.2-1.0 part of borneol.
The invention ensures that various traditional Chinese medicine components have synergistic effect on proper medicine effect by reasonably taking the components, wherein the monarch drug amount is larger, the ministerial drug, the auxiliary drug and the adjuvant drug are taken together for synergistic effect, the curative effect is good, and the treatment course is short.
The preferred pharmaceutical composition for resisting papilloma virus infection comprises the following raw materials in parts by weight:
4 parts of raw astragalus, 4 parts of oldenlandia diffusa, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
On the basis of determining the types of the components, the invention carries out a large number of drug quantity design comparison, and the combination effect of the obtained drug quantity is best.
A method for preparing a pharmaceutical composition for combating papillomavirus infection, comprising the steps of:
step 1: weighing Chinese medicinal materials;
step 2: uniformly mixing the traditional Chinese medicine raw materials in the step 1 and crushing the traditional Chinese medicine raw materials into 300-400 meshes of traditional Chinese medicine superfine powder;
step 3: adding a small amount of distilled water into the superfine powder of the traditional Chinese medicine to prepare the pasty medicine.
The invention discloses a medicine feeding device which is used for feeding medicine composition, the prepared medicine composition is pasty, and a special device for feeding medicine is designed for conveniently and uniformly smearing medicine on vagina and cervix.
The invention preferably provides a medicine feeding device which comprises a medicine charging tube and a medicine feeder, wherein the medicine charging tube is filled with the medicine composition, and the medicine charging tube is inserted into the medicine feeder when the medicine is fed, and the medicine feeder is inserted into vagina again for use.
The loading tube serves to store the pharmaceutical composition, and when loading is desired, the loading tube is inserted into the applicator and the drug is applied from the applicator to the affected area.
The invention discloses a medicine feeding device, which is characterized in that a medicine charging tube comprises a tube body and a tube head, wherein a limiting part and a medicine through hole are arranged on the tube head, the limiting part is connected with the tube body, the medicine through hole penetrates through the limiting part and is communicated with the tube body, when a medicine composition is stored, the medicine through hole is closed, when the medicine composition is used, the medicine through hole is opened, and the tube head is inserted into a medicine feeder to squeeze the medicine composition into the medicine feeder.
The invention relates to a medicine feeding device, which is characterized in that a medicine feeding device comprises a medicine feeding head and a bag body, wherein the medicine feeding head is connected with the front end of the bag body, a through hole is formed in the tail of the bag body, the size of a limiting part is larger than that of the through hole, when medicine is fed, the limiting part of a pipe head penetrates through the through hole and enters the bag body, and the limiting part is clamped at the through hole, so that a medicine feeding pipe can be connected with the medicine feeding device, then medicine composition paste in the medicine feeding pipe is extruded into the medicine feeding device, and then paste medicine is fed to an affected part by extruding the medicine feeding device.
The invention preferably provides a medicine feeding device, wherein a plurality of spray holes are formed in the medicine feeding head.
Further, the front and the side of the medicine feeding head are provided with a plurality of spray holes.
The setting of orifice can make the pasty medicine reach the affected part through the orifice under the pressure when squeezing the bag body of medicine feed ware, and frontal orifice can make the medicine spray into cervical department, and lateral orifice can make the medicine spray into on the vagina lateral wall.
Further, the tube body of the charging tube is made of semitransparent PP material, and the limiting part is made of soft silica gel.
The spacing portion that soft silica gel was made has elasticity, when entering into the medicine feed ware through the through-hole, can warp and get into, and when getting into the back, can automatic recovery to original shape to when the extrusion bag body, atmospheric pressure has the extrusion effect to the through-hole so that spacing portion has airtight effect to the through-hole.
The number of the spray holes on the front side is smaller than that of the spray holes on the side, and the spray paths of the spray holes on the front side are shorter and more direct, so that medicines are easier to spray, and the spray holes are arranged to be smaller than those on the side, so that the difference between the spray amounts of the front side and the side is reduced, and the spray is more uniform.
The invention has the following advantages and beneficial effects:
1. the Chinese medicinal preparation can regulate the immune function of organisms and inhibit viruses, thereby achieving the purpose of strengthening the body resistance, promoting the balance state of Th1/Th2, changing the immune state of vagina, resisting tumors and viruses, and providing a favorable environment for transforming cervical lesions into normal tissues. The traditional Chinese medicine is used locally, and has the characteristics of small toxic and side effects, high patient acceptance, and capability of improving cervical complications and local immune microenvironment in vagina, thus having obvious advantages.
2. The pharmaceutical composition of the invention has remarkable and stable effect for treating HPV infection; the Chinese medicinal composition has the advantages of less medicinal herbs, simple preparation process, short treatment course, low cost, no toxic or side effect and suitability for wide popularization.
3. The invention designs a device specially used for applying the medicine, which has good effect and applicability.
Drawings
The accompanying drawings, which are included to provide a further understanding of embodiments of the invention and are incorporated in and constitute a part of this application, illustrate embodiments of the invention. In the drawings:
fig. 1 is a view showing a structure in which a medicine feeder and a medicine charger of the medicine feeding device of the present invention are separated.
Fig. 2 is a diagram showing the combined loading structure of the medicine feeder and the medicine charger of the medicine feeding device of the present invention.
Fig. 3 is a schematic view of the structure of the medicine feeder of the present invention.
The names of the components in the drawings are as follows:
1-charging tube, 10-tube body, 11-limit part, 12-drug-passing hole, 2-drug feeder, 20-drug-feeding head, 21-capsule body, 22-through hole and 23-spray hole.
Detailed Description
For the purpose of making apparent the objects, technical solutions and advantages of the present invention, the present invention will be further described in detail with reference to the following examples and the accompanying drawings, wherein the exemplary embodiments of the present invention and the descriptions thereof are for illustrating the present invention only and are not to be construed as limiting the present invention.
Example 1
1. The traditional Chinese medicine raw materials are prepared according to the following weight:
4 parts of raw astragalus, 4 parts of oldenlandia diffusa, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
2. The preparation process comprises the following steps:
step 1: weighing Chinese medicinal materials;
step 2: uniformly mixing the traditional Chinese medicine raw materials in the step 1 and crushing the traditional Chinese medicine raw materials into 300-400 meshes of traditional Chinese medicine superfine powder;
step 3: adding a small amount of distilled water into the superfine powder of the traditional Chinese medicine to prepare the pasty medicine.
Example 2
The difference between this example and example 1 is that the amounts of the raw materials of the Chinese medicinal materials are different as follows:
3 parts of raw astragalus, 3 parts of oldenlandia diffusa, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
Example 3
The difference between this example and example 1 is that the amounts of the raw materials of the Chinese medicinal materials are different as follows:
4 parts of raw astragalus, 4 parts of oldenlandia diffusa, 1 part of bletilla striata, 1 part of curcuma zedoary, 1 part of pokeberry root, 1 part of lithospermum and 0.2 part of borneol.
Although examples 1, 2 and 3 all have effects, example 1 has better effects from the viewpoint of strengthening body resistance, removing toxicity, removing blood stasis and promoting granulation, and the clinical experiment is performed by selecting example 1 as follows.
Clinical trials
1.1 general data
1.1.1 subject: 300 patients with HR-HPV meet the Western diagnosis standard of infection; gong Genggao dangerous papillomavirus detection is positive;
subject selection criteria: the menstrual cycle of the patients in childbearing period is basically regular, and women in non-gestational period and lactation period. No drug similar to the study was used for the last 3 months; eliminating cervical cancer, eliminating coagulation dysfunction, mental nervous system, chronic inflammation of other systems or immune system diseases, etc.
The Chinese medicinal composition is randomly divided into three groups, 100 groups of Chinese medicinal composition have no significant difference in age, illness state and illness course, and are comparable.
1.2 treatment method:
(1) treatment group: the prescription composition of the medicine in the embodiment 1 is sprayed in cervical and vagina with a medicine feeding device of 0.8-1g each time, 1 month/10 times/1 course of treatment, and 3 courses of treatment are taken every day, and medicine is stopped during menstrual period.
(2) Control group: interferon alpha-2 b gel, 1g of the drug of example 1 was applied to the cervix and vagina each time, 1 month/10 times/1 course, once every other day, 3 courses total, menstrual withdrawal.
(3) Follow-up blank: not receiving the intervention of the medicine, ordering proper exercise, enhancing physique, and observing for 3 months.
1.3 detection indicators and methods
1.3.1 factor detection and data processing
All subjects were tested for cervical HR-HPV before (week 0) and 3 months after group entry, respectively: detecting 18 types of high-risk HPV DNA known at present by adopting a 2 nd generation hybrid capture (HC-II) technology, and taking the detected RLU/CO value as a virus load result; meanwhile, 18 high-risk type HPV E6/E7 mRNA are detected by using an HPV E6/E7 mRNA detection kit and adopting a branched-DNA technology (bDNA).
1.3.2 efficacy evaluation criteria
And (3) healing: HR-HPV virus is completely negative; the effect is shown: HPV viruses are reduced in number, or viral load is reduced, compared to the pre-treatment type, but not all are negative; invalidation: HPV virus persists without turning negative.
1.4 statistical treatment: statistical analysis using SPSS 24.0 software
2 results and analysis
Observations were made for HR-HPV negative results after different treatment periods performed on three groups of patients, respectively. The interferon group falls off 2 cases, the blank group falls off 5 cases, and the statistics show that the HPV negative conversion rate after 3 months of the traditional Chinese medicine treatment group is 89.00% (89/100), the interferon control group is 55.10% (54/98), and the blank follow-up group is 37.89% (36/95). The traditional Chinese medicine group has obviously higher negative conversion rate than the other two groups, and the difference has statistical significance (P < 0.05).
Example 4
As shown in fig. 1, fig. 2 and fig. 3, a medicine feeding device is used for feeding a medicine composition, and comprises a medicine feeding tube 1 and a medicine feeder 2, the medicine feeding tube 1 comprises a tube body 10 and a tube head, a limit part 11 and a medicine feeding hole 12 are formed in the tube head, the limit part 11 is connected with the tube body 10, the medicine feeding hole 12 penetrates through the limit part 11 and is communicated with the tube body 10, when the medicine composition is stored, the medicine feeding hole 12 is closed, when the medicine composition is used, the medicine feeding hole 12 is opened, the tube head is inserted into the medicine feeder 2 to squeeze the medicine composition into the medicine feeder 2, the medicine feeder 2 comprises a medicine feeding head 20 and a bag body 21, the medicine feeding head 20 is connected with the front end of the bag body 21, a through hole 22 is formed in the tail part of the bag body 21, the size of the limit part 11 of the medicine feeding tube 1 is larger than the through hole 22, and when the medicine is fed, the limit part 11 of the tube head penetrates through the through hole 22 into the bag body 21 to be clamped in the medicine feeding tube body 21, and then the medicine feeder 2 can be inserted into the medicine feeder 2 to squeeze the medicine feeder 2, and then the medicine feeder 2 is inserted into the medicine feeder 2.
The charge tube 1 serves to store the pharmaceutical composition, and when loading is required, the charge tube 1 is inserted into the medicine feeder 2 and the medicine is applied from the medicine feeder 2 to the affected part.
The front and side surfaces of the medicine feeding head 20 are provided with a plurality of spray holes 23.
The arrangement of the spray holes 23 can allow pasty medicines to reach the affected part through the spray holes 23 under the pressure when the capsule body 21 of the medicine feeder 2 is extruded, the spray holes 23 on the front side can enable the medicines to be sprayed into the cervix, and the spray holes 23 on the side can enable the medicines to be sprayed onto the lateral wall of the vagina.
The tube body 10 of the charging tube 1 is made of semitransparent PP material, and the limiting part 11 is made of soft silica gel.
The capsule body 20 of the medicine feeder 2 is made of semitransparent PP material.
The spacing portion 11 that soft silica gel was made has elasticity, when entering into medicine feed ware 2 through hole 22, can warp and get into, and when getting into the back, can automatic recovery to original shape to when pressing the bag body 21, the atmospheric pressure has the extrusion effect to through hole 22 makes spacing portion 11 to have airtight effect to through hole 22, and the pasty medicine of being convenient for spouts from orifice 23, and it is convenient to go up the medicine.
The number of the spray holes 23 on the front side is smaller than that of the spray holes 23 on the side, and the spray paths of the spray holes 23 on the front side are shorter and more direct, so that the spray holes 23 are arranged to be smaller than those on the side, the difference between the spray amounts on the front side and the side is conveniently reduced, and the spray is more uniform.
After the medicine feeding head 20 of the medicine feeder 2 is inserted into the vagina, the pasty medicine is sprayed out by pressing the bag body 21, so that the medicine can be sprayed on the cervix and the side wall of the vagina at one time, and the medicine feeding device is convenient and high in efficiency.
The medicine filling device is a disposable packing tube, the end part of the medicine through hole 12 is sealed to prevent the medicine from being wetted when the medicine is stored, so that a patient can take the medicine to place the medicine in home for use, and when medicine is required to be filled, the medicine through hole 12 needs to be cut off and then is inserted into the medicine feeding device 2.
The drug delivery device 2 of the present invention is reusable and can be sterilized with alcohol prior to use.
The using method is as follows:
firstly, the medicine through hole 12 of the medicine charging tube 1 is cut off, so that the medicine through hole 12 is communicated with the outside, then the tube head is inserted into the bag body 21 of the medicine feeder 2 through the through hole 22 of the medicine feeder 2, as shown in fig. 2, at the moment, the tube body 10 of the medicine charging tube 1 is extruded, the pasty medicine enters into the bag body 21 of the medicine feeder 2 under the action of pressure, the medicine feeding head 20 of the medicine feeder 2 is inserted along the vagina, the bag body 21 is pressed, and the pasty medicine is sprayed out along the spray hole 23 under the action of pressure.
The foregoing description of the embodiments has been provided for the purpose of illustrating the general principles of the invention, and is not meant to limit the scope of the invention, but to limit the invention to the particular embodiments, and any modifications, equivalents, improvements, etc. that fall within the spirit and principles of the invention are intended to be included within the scope of the invention.
Claims (3)
1. The pharmaceutical composition for resisting papilloma virus infection is characterized by comprising the following raw materials in parts by weight:
3-5 parts of raw astragalus, 3-5 parts of oldenlandia diffusa, 1-3 parts of bletilla striata, 1-3 parts of curcuma zedoary, 1-3 parts of pokeberry root, 1-3 parts of lithospermum and 0.2-1.0 part of borneol.
2. The pharmaceutical composition for resisting papillomavirus infection according to claim 1, wherein the raw materials of the medicine consist of the following components in parts by weight:
4 parts of raw astragalus, 4 parts of oldenlandia diffusa, 2 parts of bletilla striata, 2 parts of curcuma zedoary, 2 parts of pokeberry root, 2 parts of lithospermum and 0.5 part of borneol.
3. A method for preparing a pharmaceutical composition for combating papillomavirus infection, comprising the steps of:
step 1: weighing the Chinese medicinal materials according to claims 1 and 2;
step 2: uniformly mixing the traditional Chinese medicine raw materials in the step 1 and crushing the traditional Chinese medicine raw materials into 300-400 meshes of traditional Chinese medicine superfine powder;
step 3: adding a small amount of distilled water into the superfine powder of the traditional Chinese medicine to prepare the pasty medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211556055.1A CN115887602B (en) | 2022-12-06 | 2022-12-06 | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211556055.1A CN115887602B (en) | 2022-12-06 | 2022-12-06 | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115887602A CN115887602A (en) | 2023-04-04 |
| CN115887602B true CN115887602B (en) | 2024-01-26 |
Family
ID=86470898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211556055.1A Active CN115887602B (en) | 2022-12-06 | 2022-12-06 | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115887602B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908559A (en) * | 2012-09-26 | 2013-02-06 | 韩临晓 | External-use Chinese herbal medicine preparation for curing human papilloma virus infection |
| CN103041283A (en) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | Externally-used traditional Chinese medicine composition for treating cervical HPV infection and preparation method thereof |
-
2022
- 2022-12-06 CN CN202211556055.1A patent/CN115887602B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103041283A (en) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | Externally-used traditional Chinese medicine composition for treating cervical HPV infection and preparation method thereof |
| CN102908559A (en) * | 2012-09-26 | 2013-02-06 | 韩临晓 | External-use Chinese herbal medicine preparation for curing human papilloma virus infection |
Non-Patent Citations (1)
| Title |
|---|
| 益气活血解毒中药联合树突状细胞疫苗 对荷瘤小鼠免疫抑制的调控;卢雯平等;中国中医药信息杂志;第20卷(第3期);第46-48, 54页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115887602A (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102370725A (en) | Traditional Chinese medicine compound preparation for treating chronic pelvic inflammation and preparation method thereof | |
| CN101085299A (en) | Traditional Chinese medicinal composition for treating female pelvic inflammation and its application | |
| CN102363020B (en) | Chinese medicinal composition for treating proliferation of mammary gland | |
| CN1772152A (en) | Chinese medicine prepn for regulating menstruation and treating sterility | |
| CN1966052A (en) | Tablet containing red sage root and astragalus root for removing blood stasis and preparation process thereof | |
| CN102210844A (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN103223155A (en) | Medicament for treating postpartum hemorrhage | |
| CN101214315B (en) | Medicament for preventing and treating gynaecologic hemorrhage and preparation thereof | |
| CN115887602B (en) | Pharmaceutical composition for resisting papillomavirus infection, preparation method and medicine feeding device | |
| CN101979031B (en) | Medicament for treating hemorrhoids and preparation method thereof | |
| CN102018754A (en) | Vaginal effervescent tablet and making process thereof | |
| CN104435484A (en) | Seven connected traditional Chinese medicine packets for treating colorectal cancer | |
| CN103301415B (en) | Medicinal composition for preventing and treating intrauterine adhesion after induced abortion operation and application thereof | |
| CN101332282A (en) | Traditional Chinese medicine composition for treating gynecologic diseases reduced by kidney deficiency and genitals coldness | |
| CN103585573A (en) | Oral medicine for treating hysteromyoma | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN1259078C (en) | Chinese medicine for treating women's chronic pelvic infection | |
| CN103599204B (en) | Chinese medicine composition and its preparation method and application | |
| CN105250519A (en) | Traditional Chinese medicine composition for relieving sequelae of pelvic inflammatory disease and application of traditional Chinese medicine composition | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN105213972A (en) | A kind of pharmaceutical preparation of promoting blood circulation to remove obstruction in the collateral and application thereof | |
| CN100411672C (en) | A medicinal composition for treatment of psoriasis | |
| CN101502632B (en) | Chinese medicine for cholecystitis | |
| CN102178755A (en) | Medicament for preventing miscarriage | |
| CN108014252B (en) | Pharmaceutical composition, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |